Recent advances in methodology for clinical trials in small populations: the InSPiRe project

Abstract

Where there are a limited number of patients, such as in a rare disease, clinical trials in these small populations present several challenges, including statistical issues. This led to an EU FP7 call for proposals in 2013. One of the three projects funded was the Innovative Methodology for Small Populations Research (InSPiRe) project. This paper summarizes the main results of the project, which was completed in 2017. The InSPiRe project has led to development of novel statistical methodology for clinical trials in small populations in four areas. We have explored new decision-making methods for small population clinical trials using a Bayesian decision-theoretic framework to compare costs with potential benefits, developed approaches for targeted treatment trials, enabling simultaneous identification of subgroups and confirmation of treatment effect for these patients, worked on early phase clinical trial design and on extrapolation from adult to pediatric studies, developing methods to enable use of pharmacokinetics and pharmacodynamics data, and also developed improved robust meta-analysis methods for a small number of trials to support the planning, analysis and interpretation of a trial as well as enabling extrapolation between patient groups. In addition to scientific publications, we have contributed to regulatory guidance and produced free software in order to facilitate implementation of the novel methods.

arXiv comment9 pages, 3 figures

References in corpus (8)

• Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies
• Meta-analysis of few small studies in orphan diseases
• Meta-analysis of two studies in the presence of heterogeneity with applications in rare diseases
• Interleukin-2 receptor antagonists for pediatric liver transplant recipients: A systematic review and meta-analysis of controlled studies
• Discrete approximation of a mixture distribution via restricted divergence
• Optimizing Trial Designs for Targeted Therapies
• Using phase II data for the analysis of phase III studies: an application in rare diseases
• Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions

Cited by in corpus (2)

• In silico clinical trials in drug development: a systematic review
• Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors